Zacks Research Expects Weaker Earnings for Core Laboratories

Key Points

• Zacks Research lowered its Q3 2026 EPS forecast for Core Laboratories to $0.17 from $0.18, while full-year earnings are expected at $0.56 per share.
• Core Laboratories shares were trading down 2.3% at $12.21, well below their 52-week high of $20.36. The stock has a “Moderate Buy” consensus rating and a $21 average price target.
• The company’s latest quarterly results beat EPS expectations, but revenue fell 4.3% year over year; institutional investors own 97.81% of the stock, and CEO Lawrence Bruno recently purchased 5,000 shares.

Core Laboratories Inc. (NYSE:CLB - Free Report) - Research analysts at Zacks Research cut their Q3 2026 EPS estimates for shares of Core Laboratories in a note issued to investors on Monday, September 14th. Zacks Research analyst Team now anticipates that the oil and gas company will earn $0.17 per share for the quarter, down from their previous forecast of $0.18. The consensus estimate for Core Laboratories' current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Core Laboratories' Q1 2027 earnings at $0.11 EPS and FY2028 earnings at $1.11 EPS.

Several other equities analysts have also recently issued reports on CLB. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. Johnson Rice upgraded shares of Core Laboratories from a "hold" rating to a "buy" rating and set a $21.00 price target on the stock in a report on Thursday, August 13th. Finally, Weiss Ratings raised shares of Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.

Core Laboratories Trading Down 2.3%

CLB opened at $12.21 on Tuesday. Core Laboratories has a one year low of $9.79 and a one year high of $20.36. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. The business has a 50 day simple moving average of $11.81 and a two-hundred day simple moving average of $13.72. The firm has a market capitalization of $560.15 million, a price-to-earnings ratio of 21.80, a PEG ratio of 2.47 and a beta of 1.08.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $124.61 million for the quarter, compared to analysts' expectations of $126.26 million. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The company's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

Institutional Trading of Core Laboratories

Hedge funds have recently modified their holdings of the business. Summit Securities Group LLC bought a new position in shares of Core Laboratories in the 1st quarter worth about $31,000. Hantz Financial Services Inc. boosted its stake in Core Laboratories by 124.7% during the fourth quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company's stock worth $51,000 after acquiring an additional 1,763 shares in the last quarter. State of Wyoming grew its holdings in Core Laboratories by 267.7% in the first quarter. State of Wyoming now owns 4,626 shares of the oil and gas company's stock worth $78,000 after purchasing an additional 3,368 shares during the period. Corient Private Wealth LP purchased a new stake in Core Laboratories in the second quarter worth about $141,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Core Laboratories during the second quarter valued at approximately $156,000. Institutional investors own 97.81% of the company's stock.

Insiders Place Their Bets

In other news, CEO Lawrence Bruno acquired 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The stock was acquired at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the completion of the acquisition, the chief executive officer owned 262,438 shares in the company, valued at $2,829,081.64. This trade represents a 1.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.26% of the stock is currently owned by insiders.

Core Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Monday, August 10th were given a dividend of $0.01 per share. The ex-dividend date was Monday, August 10th. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. Core Laboratories's payout ratio is currently 7.14%.

About Core Laboratories

Core Laboratories N.V. NYSE: CLB is a global provider of reservoir description and production enhancement services for the oil and natural gas industry. The company helps exploration and production companies evaluate subsurface formations, characterize reservoirs and improve the recovery of hydrocarbons from existing fields.

Core Laboratories' reservoir description activities include laboratory analysis of rock and fluid samples, core analysis, special core analysis, fluid and pressure-volume-temperature studies, geochemical services and related geological and petrophysical evaluations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.